Pregabalin Market Insights: Growth, Trends, and Forecast (2024-2030)

𝐏𝐫𝐞𝐠𝐚𝐛𝐚𝐥𝐢𝐧'𝐬 𝐄𝐱𝐩𝐚𝐧𝐝𝐢𝐧𝐠 𝐑𝐨𝐥𝐞 𝐢𝐧 𝐏𝐚𝐢𝐧 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐍𝐞𝐮𝐫𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐂𝐚𝐫𝐞

Pregabalin, a medication commonly used to treat neuropathic pain, fibromyalgia, and certain types of anxiety disorders, is seeing expanding demand across the globe. Its effectiveness in treating conditions such as epilepsy and chronic pain, along with growing awareness about mental health issues, is driving its market adoption.

Therapeutic Uses: Pregabalin is increasingly prescribed for neuropathic pain, diabetic neuropathy, post-herpetic neuralgia, and fibromyalgia, with a growing number of doctors recognizing its potential in treating generalized anxiety disorder and seizures.
Market Drivers: The primary factors contributing to the growth of the pregabalin market include an aging population, rising prevalence of chronic conditions, and greater access to healthcare services.

𝐄𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐆𝐫𝐨𝐰𝐭𝐡 𝐑𝐚𝐭𝐞 𝐟𝐨𝐫 𝐏𝐫𝐞𝐠𝐚𝐛𝐚𝐥𝐢𝐧 𝐌𝐚𝐫𝐤𝐞𝐭

The pregabalin market was estimated to be worth US$ 828.56 million in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 3.69% from 2024 to 2030. By 2030, the pregabalin market is led by the neuropathic pain category.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐝𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐝𝐚𝐭𝐚 𝐚𝐧𝐝 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐛𝐲 𝐯𝐢𝐞𝐰𝐢𝐧𝐠 𝐭𝐡𝐞 𝐬𝐚𝐦𝐩𝐥𝐞 @https://www.maximizemarketresearch.com/request-sample/109027/

𝐌𝐞𝐫𝐠𝐞𝐫𝐬 & 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧𝐬: 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐂𝐨𝐧𝐬𝐨𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐌𝐨𝐯𝐞𝐬

The pregabalin market has seen a series of mergers and acquisitions, as major pharmaceutical companies look to consolidate their positions in the growing market.

Vietnam: Local pharmaceutical company Traphaco has entered into a partnership with a global drug manufacturer, acquiring a stake in pregabalin production to expand its market share in Southeast Asia.
Thailand: Thai Pharma has successfully acquired a manufacturing unit in Thailand to produce generic pregabalin, making it more affordable for local patients and contributing to market growth in the region.
Singapore: Singapore-based Bio-X Pharma recently merged with a European-based pharmaceutical company, bringing advanced pregabalin formulation technology to the Asian market.
Japan: Takeda Pharmaceutical Company has acquired a significant stake in Mylan, enhancing its ability to distribute pregabalin-based products in Japan and across Asia.
South Korea: South Korea's Hanmi Pharmaceutical has developed strategic alliances with global pharmaceutical companies, including Pfizer, to expand its pregabalin offerings in the region, particularly focusing on generic versions of the drug.
European Union: Novartis has announced the acquisition of Sandoz, further consolidating its position in the pregabalin market in Europe, especially in the generics segment.
United States: In the US, Eli Lilly has completed a merger with AbbVie in a bid to dominate the global pregabalin market, particularly focusing on the treatment of pain disorders and neurological diseases.

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: 𝐊𝐞𝐲 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐊𝐞𝐲 𝐌𝐚𝐫𝐤𝐞𝐭𝐬

Vietnam: The pregabalin market in Vietnam is growing rapidly due to increased awareness of neurological disorders and pain management. The government is making efforts to expand access to affordable medications.
Thailand: Thailand's pregabalin market is expanding due to a growing number of healthcare facilities and increasing adoption of advanced drug therapies. Thailand also serves as a production hub for several global generics manufacturers.
Singapore: Singapore is witnessing an increase in pregabalin prescriptions, supported by the country's advanced healthcare system and the high adoption of modern pharmaceuticals.
Japan: In Japan, pregabalin has become a key drug in the treatment of fibromyalgia and neuropathic pain. With an aging population, the demand for pain management solutions is growing steadily.
South Korea: South Korea's healthcare sector is rapidly advancing, leading to the increased use of pregabalin as a primary treatment for chronic pain and anxiety disorders.
European Union: Pregabalin is widely used across the EU, especially in the treatment of neuropathic pain and anxiety disorders. With several ongoing mergers and acquisitions, the European market is expected to remain competitive and continue its growth trajectory.
United States: The US remains the largest market for pregabalin, driven by its widespread use in treating chronic pain, neurological conditions, and anxiety disorders. The FDA's approval of generic versions has made pregabalin more accessible to a broader patient base.

𝐔𝐧𝐥𝐨𝐜𝐤 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐛𝐲 𝐞𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐬𝐚𝐦𝐩𝐥𝐞 𝐯𝐢𝐚 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤 @https://www.maximizemarketresearch.com/request-sample/109027/

𝐌𝐚𝐫𝐤𝐞𝐭 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭: 𝐏𝐫𝐞𝐠𝐚𝐛𝐚𝐥𝐢𝐧 𝐌𝐚𝐫𝐤𝐞𝐭'𝐬 𝐆𝐫𝐨𝐰𝐭𝐡 𝐓𝐫𝐚𝐣𝐞𝐜𝐭𝐨𝐫𝐲

Key factors contributing to this growth include:

Rising Prevalence of Neurological Disorders: Conditions like epilepsy, fibromyalgia, and diabetic neuropathy are on the rise globally, contributing to increased demand for pregabalin.
Growing Generic Segment: The increasing availability of generic pregabalin is expected to boost market growth, particularly in regions with a high demand for affordable medications.
Technological Advancements: Innovations in drug delivery systems and the formulation of more effective pregabalin-based products are expected to drive market growth, particularly in developed economies.

𝐀 𝐁𝐫𝐢𝐠𝐡𝐭 𝐅𝐮𝐭𝐮𝐫𝐞 𝐟𝐨𝐫 𝐏𝐫𝐞𝐠𝐚𝐛𝐚𝐥𝐢𝐧

With rising demand for effective treatments for neurological conditions and chronic pain, the pregabalin market is positioned for significant growth. Strategic mergers and acquisitions are reshaping the competitive landscape, as companies seek to leverage new technologies and expand their geographic footprint. The outlook for the global pregabalin market remains positive, with continued growth expected across regions in the coming years.

𝐆𝐞𝐭 𝐚 𝐜𝐥𝐨𝐬𝐞𝐫 𝐥𝐨𝐨𝐤 𝐚𝐭 𝐭𝐡𝐞 𝐠𝐚𝐦𝐞-𝐜𝐡𝐚𝐧𝐠𝐢𝐧𝐠 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐬 𝐝𝐫𝐢𝐯𝐢𝐧𝐠 𝐬𝐮𝐜𝐜𝐞𝐬𝐬 :https://www.maximizemarketresearch.com/request-sample/109027/

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧:

𝐛𝐲 𝐏𝐫𝐨𝐝𝐮𝐜𝐭

Capsules
Oral Solutions
Others

The market is divided into three segments based on the product: capsules, oral solutions, and others. The oral solutions pregabalin market is anticipated to expand at a compound annual growth rate (CAGR) between 2024 and 2030. Pregabalin oral solutions help manage certain kinds of seizures. This medication is used to treat nerve pain. It is used to treat fibromyalgia. You might receive it for a number of reasons. These are the main elements of pregabalin oral solutions that support the expansion of the worldwide market over the 2024-2030 projection period.

𝐛𝐲 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧

Epilepsy
Neuropathic Pain
Anxiety Disorders
Others

The market is divided into categories such as anxiety disorders, neuropathic pain, epilepsy, and others. By 2030, it is anticipated that the neuropathic pain segment would have the biggest market share. One of the most prevalent signs of neuropathic pain is burning or shooting pain. The most frequent cause is damage to the nerves. Inhibiting pain signals is how pregabalin reduces neuropathic pain. The market is anticipated to grow as a result of an increase in neuropathic pain and risk factors including HIV and diabetes. The International Diabetes Federation estimates that 9.3% of adults worldwide have diabetes in 2019, and by 2045, that percentage is predicted to increase to roughly 11%.

𝐛𝐲 𝐄𝐧𝐝-𝐔𝐬𝐞𝐫𝐬

Hospitals
Specialty Clinics
Homecare
Others

𝐛𝐲 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

𝐆𝐞𝐭 𝐚 𝐝𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 :https://www.maximizemarketresearch.com/market-report/global-pregabalin-market/109027/

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:

1. Pfizer Inc.
2. Torrent Pharmaceuticals Ltd.
3. Lupin Limited
4. Zydus Cadila Healthcare Ltd.
5. Cipla Limited
6. Genesis Remedies
7. Sanofi
8. Medley Pharmaceuticals Limited
9. Genesis Biotec Inc.
10.Biomax
11.ZCL Chemicals Ltd.
12.Olon S.p.A.
13.AASraw Biochemical Technology Co., Ltd.
14.Changzhou Pharmaceutical Factory (CPF)
15.Almelo Pvt. Ltd.
16.Angels Pharma India Pvt. Ltd.
17.ARITE Pharmaceutical Co., Ltd.
18.Bal Pharma Limited.
19.Bazayan and Co.
20.Aurobindo Pharma Ltd.
21.Hikal Ltd.
22.Glenmark Life Sciences
23.Dongbang FTL

𝐂𝐡𝐞𝐜𝐤 𝐨𝐮𝐭 𝐨𝐮𝐫 𝐭𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐬𝐭𝐮𝐝𝐢𝐞𝐬 𝐭𝐨 𝐮𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐬𝐡𝐢𝐟𝐭𝐬 :

♦ Global Exterior Doors Market https://www.maximizemarketresearch.com/market-report/global-exterior-doors-market/22251/

♦ Global Marine Big Data Market https://www.maximizemarketresearch.com/market-report/global-marine-big-data-market/57598/

♦ Global GaN on Diamond Semiconductor Substrates Market https://www.maximizemarketresearch.com/market-report/global-gan-on-diamond-semiconductor-substrates-market/19821/

♦ Global Aluminum Chloride Hexahydrate Market https://www.maximizemarketresearch.com/market-report/global-aluminum-chloride-hexahydrate-market/81197/

♦ Global Bleached Linter Cellulose Market https://www.maximizemarketresearch.com/market-report/global-bleached-linter-cellulose-market/91894/

♦ Global Tank Level Monitoring System Market https://www.maximizemarketresearch.com/market-report/global-tank-level-monitoring-system-market/96647/

♦ Global Knitwear Market https://www.maximizemarketresearch.com/market-report/global-knitwear-market/19993/

♦ Solketal Market https://www.maximizemarketresearch.com/market-report/solketal-market/146640/

♦ Positive Displacement Blowers Market https://www.maximizemarketresearch.com/market-report/positive-displacement-blowers-market/147304/

♦ Hodgkin Lymphoma Treatment Market https://www.maximizemarketresearch.com/market-report/hodgkin-lymphoma-treatment-market/124690/

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬:

MAXIMIZE MARKET RESEARCH PVT. LTD.
3rd Floor, Navale IT park Phase 2,
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India.
+91 9607365656
sales@maximizemarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.

This release was published on openPR.